US EditionmRNA vaccine hope for pancreatic cancer, fertility facts, smarter skin and hair care
Of 16 patients, eight mounted an immune response and seven were alive six years later, researchers said.
- Patients who received a personalized BioNTech mRNA vaccine for pancreatic cancer and mounted an immune response lived longer than those who did not, according to results presented at a major cancer research conference.
- In the trial, 16 patients underwent surgery to remove tumors, followed by chemotherapy and immunotherapy, with tumor samples sent to BioNTech to create a personalized vaccine for each individual.
- Of the 16 patients enrolled, eight showed a successful immune response, and seven of those eight remained alive six years after the trial began, a notable finding for a disease with such a poor prognosis.
- Caution is warranted regarding these encouraging results, as the trial covered only 16 patients and larger studies will be required before this vaccine becomes a standard treatment option.
- Pancreatic cancer claims the lives of 88 percent of those diagnosed, and this vaccine trial highlights potential progress in the half-century-old War on Cancer, where tumors remain moving targets that evade most treatments.
24 Articles
24 Articles
Pancreatic cancer is one of the most deadly cancers, but a small study gives patients hope, including Donna Gustafson.
The ROI of Beating Cancer
Talk about pro-progress news—and a pro-progress lesson for government. New data from a cancer vaccine trial is a good reminder of what the half-century-old War on Cancer is actually worth. Patients who received a personalized mRNA vaccine for pancreatic cancer and mounted an immune response lived longer than those who did not, according to results presented at a major cancer research conference. Pancreatic cancer is notoriously lethal, killing m…
Pancreatic cancer patients continue to thrive after early trial of mRNA-based vaccine
Almost half of the participants in an early trial of an mRNA-based vaccine to fight pancreatic cancer were alive and well up to six years after treatment, according to new research. CNN’s Brianna Keilar speaks with Dr. Vinod Balachandran, director of the Olayan Center for Cancer Vaccines at Memorial Sloan Kettering Cancer Center, who led the study.
Krem2 News
mRNA vaccine hope for pancreatic cancer; fertility facts; smarter skin and hair care
Some promising things are happening in health news, including a possible personalized vaccine against pancreatic cancer. Hear what doctors are doing. (WKYC)
mRNA Cancer Vaccine Shows Lasting Results Against One of America's Deadliest Cancers
For decades, pancreatic cancer has been one of medicine’s most resistant targets. Standard treatments offered limited survival benefit. Immunotherapy, which has transformed outcomes in other cancers, largely failed to gain traction here. That picture is beginning to shift. New follow-up data from a Phase 1 clinical trial at Memorial Sloan Kettering Cancer Center show that a personalized mRNA vaccine produced durable immune responses in some pati…
Coverage Details
Bias Distribution
- 78% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
